Dr. Reddy s Laboratories Limited Investor Presentation June 2013 LIFE. RESEARCH. HOPE
|
|
- Mabel Richards
- 6 years ago
- Views:
Transcription
1 Dr. Reddy s Laboratories Limited Investor Presentation June 2013 LIFE. RESEARCH. HOPE
2 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as anticipates, believes, estimates, expects, intends, plans, predicts, projects and similar expressions. Risks and uncertainties that could affect us include, without limitation: General economic and business conditions in India; The ability to successfully implement our strategy, our research and development efforts, growth and expansion plans and technological changes; Changes in the value of the Rupee and other currency changes; Changes in the Indian and international interest rates; Allocations of funds by the Government; Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry; Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and Changes in political conditions in India. Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events. 1
3 Company Overview Looking Back Looking Forward Business Updates 2
4 Our Strategy Leverage industry-leading science & technology, product offering and customer service with execution excellence. Our Values Integrity and Transparency Safety Quality Productivity Respect for Individual Collaboration and Teamwork Sustainability 3
5 Overview Integrated business model spanning 3 segments. Global Generics Global access to affordable medicines Pharmaceutical Services & Active Ingredients Proprietary Products Meeting unmet medical needs... Deep Understanding Partner of Choice FY13 Revenue mix 71% of total Finished dosage businesses in distribution-driven as well as doctor-driven markets Strategic focus on key large markets North America, India, Russia / CIS & other Emerging Market territories and Europe FY13 Revenue mix 26% of total Amongst the leaders in supply of generic APIs globally Customers include generic manufacturers, innovator companies Focus on building sustainable and profitable branded proprietary business Efforts in new drug discovery, differentiated formulations & Biologics (with a focus on Generic Biopharmaceuticals) * Revenue converted at the average billing rate for FY 13. 4
6 Minimizing Business risk Diversified Model Strong vertically integrated portfolio of businesses, geographies & products. Global Generics Generics : North America // Germany // Rest of Europe Branded Generics : India // Russia & CIS // Other Emerging Markets // GSK Alliance Generic Biopharmaceuticals Dr. Reddy s PSAI Active Ingredients Custom Pharmaceutical Services Proprietary Products Specialty/Differentiated Formulations 5
7 Company Overview Looking Back Looking Forward Business Updates 6
8 The Last Decade Acquired Roche's API business (Mexico) Launched Reditux (Rituximab) World's 1 st monoclonal antibody biosimilar in India $1 Bn in revenue 2006 Acquired betapharm simvastatin / finastride AG Acquired GSK s Bristol penicillin facility 10 th year of NYSE listing Strategic alliance with GSK for emerging markets Acquired Octoplus Merck Serono deal for biosimilars $2 Bn in revenue Launched Cresp ( darbepoetin alfa) in India - world s first generic and only one in India Acquired BASF s formulation manufacturing unit and Dow Pharma s small Molecules Business Launch of US specialty business, Promius TM Pharma. Built the foundations for a strong business. Moved up the value chain. Strengthened capabilities. Achieved scale and global presence. Acquired to aid growth. $ 463 Mn Revenue converted at respective years average billing rate. Revenue CAGR 19 % $ 2.23 Bn 7
9 Infrastructure : Global footprint Leiden Oral solids and topical Louisiana Princeton Tennessee Cambridge Chiral technology, mpegs Mexico Steroids Oral solids and suspensions India Active ingredients, oral solids, injectables API (8) Finished Dosages (9) Biologics (1) Technology Development Centers (4) R&D Centers Integrated Product Development Organization [IPDO] and NCE R&D center in Hyderabad, India Aurigene R&D center in Bangalore, India, Princeton Numbers in brackets indicate number of facilities/plants 8
10 Our Strengths 1. Industry leading chemistry skills Several niche product opportunities in API & generics (tacrolimus / lansoprazole / omeprazole mg OTC / fondaparinux / fexofenadine product family / Ibandronate / metoprolol succinate etc) 2. Early mover advantage in biosimilars Global generic launch of rituximab 4 products in marketing portfolio 3. Infrastructure 25+ billion units in generics capacities 9 formulation (4 USFDA approved) and 8 API mfg facilities (All USFDA approved) 4. Diversified business model Risk diversified across different nature of businesses and across countries 5. High vertical integration Global leader in DMF filings (577 Mar 13) 9
11 Robust improvement in financial metrics Base Revenue ($ Mn) 1,353 1,428 1,639 1,918 2,232 EBITDA ($ Mn) 332 One-off contribution from exclusivity sales FY09 FY10 FY11 FY12 FY13 Base revenues represent revenues excluding significant exclusivity sales All figures converted at respective periods average translation/ delivered rate FY09 FY10 FY11 FY12 FY13 All figures converted at respective periods average translation/ delivered rate PAT % to sales 12% 13% 14% 16% 15% 16% 18% 18% 24% 23% FY09 FY10 FY11 FY12 FY13 PAT adjusted for one time non cash impairment charges & other non recurring costs FY09 FY10 FY11 FY12 FY13 RoCE mentioned above is pre-tax Operating RoCE adjusted for one time non cash impairment charges & other non recurring costs 10
12 Company Overview Looking Back Looking Forward Business Updates 11
13 Future Growth Drivers Innovation (R&D) Organic Growth Productivity Inorganic Growth Complex generics and injectables Biosimilars Differentiated Formulations Breadth and Depth Customer relationships and engagement Procurement of product materials and packaging Manufacturing processes Product and market rationalisation Alliances manufacturing & marketing Capability based Acquisitions In-licensing and brand acquisitions Marketing and distribution Corporate Governance, Sustainability and Operations excellence 12
14 Small molecules Complex generics Current Performance Development catalysts Future Outlook Complex Generics Growing pipeline of limited competition products in US E.g: fondaparinux, tacrolimus, omeprazole Mg OTC, metoprolol etc Technology Platforms to aid complex generic dev.. Mpegs Chiral technology Biocatalysis technology Polymer technology Improving R&D productivity & filings rate Greater share of filings to belong to niche category 13
15 Company Overview Looking Back Looking Forward Business Updates 14
16 Global Generics: North America Base Revenues ($ Mn) Excluding upside revenues Upside Revenues FY09 FY10 FY11 FY12 FY13 $156 mn $54 mn $100 mn Portfolio Growing portfolio of limited competition products Mar-13 Mar-12 Tacrolimus 45% 22% Lansoprazole 21% 19% Ziprasidone 24% 27% Fondaparinux 27% 24% (Volume Generics Market; Source: IMS Health Inc Mar 2013) Pipeline 200 Cumulative ANDAs 65 pending ANDAs (~$32 bn of innovator brand sales value) 38 Para IVs 8 First-to-Files (FTFs) 15
17 Global Generics: North America Continued growth in the period upto FY17 Service Level excellence Continued strong engagement with strategic customers Strategic Focus High Quality portfolio Steady growing business Mix of limited competition and complex generics products to significantly enhance new launches annually with launch-year 16
18 Emerging Markets Foot Print Emerging markets are projected to drive the global pharmaceutical market growth CIS Russia Jamaica Venezuela Brazil China India Myanmar Vietnam Srilanka Australia South Africa New Zealand 17
19 Global Generics: Emerging Markets Russia Revenue ($ Mn) th largest branded generic Robust & consistent outperformance of industry growth over the years FY09 FY10 FY11 FY12 FY13 Top 6 Rx products Top 2 in market shares Top Products Market Share Rank Omez 60% 1 Nise 63% 1 Ketorol 58% 1 Ciprolet 44% 1 Cetrine 33% 2 Senade 94% 1 Increasing mix of OTC sales 29% 34% 18% 26% 13% FY09 FY10 FY11 FY12 FY13 Source: Pharmexpert YTD Dec
20 Global Generics: Emerging Markets Russia Focus & Build portfolio in select Therapeutic areas : Focus Therapeutic areas Gastrointestinal Pain Anti-infectives Dermatology Cardiovascular Gynaecology Existing Grow Mega brands (brands > $20 mn) Scale-up OTC portfolio Build portfolio of differentiated New & difficult to manufacture Biosimilars & Oncology products 19
21 Global Generics: India Revenue (Rs Crs) 848 1,016 1,169 1,294 1,456 Strong relationship with GP/CPs Coverage of > 200,000 doctors Overall prescription ranking at 11 th (Source: July-October 12 SMSRC data) FY09 FY10 FY11 FY12 FY13 Growing portfolio of biosimilars FY09 FY10 FY11 FY12 FY13 88 Rs Crs 110 Strong market share in Top brands Top 10 Brands Market Share Rank Omez 54% 1 Nise 49% 1 Stamlo 19% 1 Omez-DSR 24% 2 Reditux NA ~1 Stamlo Beta 12% 2 Razo 14% 1 Atocor 5% 6 Razo-D 9% 1 Econorm 44% 1 20
22 Global Generics: India Focus & Build portfolio in select Therapeutic areas : Focus Therapeutic areas Gastrointestinal Pain Anti-infectives Dermatology Cardiovascular Oncology Existing Grow & sustain Mega brands (brands > Rs. 30 crs) Scale-up Biosimilars & Oncology 1 new biosimilar launch annually Enhance customer New engagement through scale up of Dr. Reddy s Foundation for Health Education 21
23 Global Generics : Europe Revenue ( Mn) FY09 FY10 FY11 FY12 FY13 Europe Strong cost control measures Launch of new products outside the scope of tenders Selective approach of picking portfolio 22
24 Pharmaceutical Services & Active Ingredients Revenue ($ Mn) FY09 FY10 FY11 FY 12 FY 13 Visibility of new launches, new customer lockins and improving order book status Pipeline 17 DMFs filed in Q4 FY13 Cumulatively 577 DMFs (US 184) All figures converted at respective years average translation rate 23
25 Proprietary Products Strategy Calibrate investments and build a selfsustainable, commercially valuable portfolio of Specialty-oriented proprietary products Approach Pursue well-defined niche and semiblockbuster Specialty opportunities with limited competition Key Aspects Pipeline Shift from NCEs to focus on low risk R&D (differentiated products) Focus on therapeutic areas of Pain Dermatology Other TAs a) Dermatology b) Pain c) Anti-infectives Alliance with GSK to focus on commercialization of differentiated products in Emerging Markets 24
26 Biologics Current Performance 1 st 1 st biosimilar biosimilar darbepoetin alfa in the monoclonal antibody in world. the world. The only available in India st biosimilar filgrastim (G-CSF) in India. A single source pegfilgrastim. The only affordable pegfilgrastim in India. Filgrastim Rituximab Darbepoetin alfa Pegfilgrastim Development catalysts Development, Manufacturing and Commercialization partnership with Merck Serono for entry into regulated markets 25
27 Dr. Reddy s Merck Serono Biosimilars deal -- Deal coverage -- Co-development Co-manufacturing Cocommercialization Global deal Portfolio of biosimilar compounds in oncology, primarily MAbs. Sharing of development costs. For non-covered products, Dr. Reddy s continues to carry out the required development / manufacturing / commercialization. Revenue allocations Merck Serono Exclusive markets Royalty arrangement Dr. Reddy s Exclusive & co-exclusive markets US market Co- commercialization 26
28 Thank You For any information please contact Investor Relations Cell : Kedar Upadhye at kedaru@drreddys.com / Saunak Savla at saunaks@drreddys.com / Milan Kalawadia (USA) at mkalawadia@drreddys.com /
29 Q4 FY13 Performance $ 613 Million 26% YoY gr $170 mn 28% to sales 37% YoY gr Revenue EBITDA R&D Filings $43 mn 7.0% to sales 6 ANDA filed 17 DMFs filed All US dollar figures based on convenience translation rate of 1USD = Rs
30 Revenue mix by segment $ mn $ mn Q4 Mar 13 Q4 Mar 12 Growth% Global Generics North America Europe India Russia & Other CIS RoW PSAI North America Europe India RoW Proprietary Products & Others Total (5) (6) All US dollar figures based on convenience translation rate of 1USD = Rs
31 FY 2013 Performance $ 2,133 Mn 26% YoY gr # $510 mn 24% to sales 30%+ YoY gr # Revenue EBITDA R&D Filings $141 mn 6.6% to sales 30% YoY gr 18 ANDA, 1 NDA filed 47 DMFs filed # - Excluding the impact of Olanzapine from FY 12 All US dollar figures based on convenience translation rate of 1USD = Rs
32 Revenue mix by segment $ mn $ mn FY2013 FY2012 Growth% Global Generics North America Europe India Russia & Other CIS RoW PSAI North America Europe India RoW Proprietary Products & Others Total 1,514 1, (7) ,133 1, All US dollar figures based on convenience translation rate of 1USD = Rs # - Excluding the impact of Olanzapine from FY12 31
33 Key Balance Sheet Items $ mn Cash & Cash Equivalents March 2013 Dec Net Operating Working Capital Property, plant & equipment Goodwill & Intangibles Loans & borrowings (current & non current) Equity & Reserves 1,341 1,225 o Capital expenditure during Q4 FY 13 $26 mn o Current Cash flow hedge options of ~ $480 mn [range of Rs 56 to Rs 59] All US dollar figures based on convenience translation rate of 1USD = Rs
Dr. Reddy s. Investor Presentation Dr. Reddy s Laboratories Limited Hyderabad, India NYSE: RDY
Dr. Reddy s Investor Presentation 2015 Dr. Reddy s Laboratories Limited Hyderabad, India NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and information that involve
More informationInvestor Presentation
Investor Presentation November 2016 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe harbor statement This presentation contains forward-looking statements and
More informationDr. Reddy s at a glance
Dr. Reddy s at a glance 22000 people 40 nationalities 200 products 30 countries One Purpose We accelerate access to affordable and innovative medicines because Dr. Reddy s at a glance 8/22/2017 2 Our Purpose
More informationDr. Reddy s JP Morgan Annual Healthcare Conference 2016
Dr. Reddy s JP Morgan Annual Healthcare Conference 2016 Saumen Chakraborty Alok Sonig Dr. Reddy s Laboratories Limited Hyderabad, India NYSE: RDY Safe harbor statement This presentation contains forward-looking
More informationInvestor Presentation November 2017
Investor Presentation November 2017 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationCompany Research. Dr Reddy s Laboratories- BUY with a Target of Rs 1,962. Investment overview- Business Overview-
Date-16-07-2012 Dr Reddy s Laboratories- BUY with a Target of Rs 1,962 Investment overview- Shareholders Information Global Generics grew by 68% to Rs 70,243mn in FY12 from Rs 53,340mn in Fy11. Therefore
More informationInvestor Presentation February 2018
Investor Presentation February 2018 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationInvestor Presentation June 2018
Investor Presentation June 2018 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and information
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation June 2018 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.2% With a Global Footprint Revenue
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation September 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.4% With a Global Footprint Revenue
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation March 2018 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.2% With a Global Footprint Revenue
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation November 2017 A Leading Pharmaceutical Company #4 One of the leading pharmaceutical companies in India 1 Market share of 4.3% With a Global Footprint Revenue
More informationCadila Healthcare Limited Investor Presentation
Cadila Healthcare Limited Investor Presentation March 2017 A Leading Pharmaceutical Company #4 Leading pharmaceutical company in India 1 Market share of 4.2% With a Global Footprint Revenue Split for 9MFY17
More informationInvestor Presentation Q1FY
Investor Presentation Q1FY19 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements".
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More informationCommerzbank German Investment Seminar 2012
Commerzbank German Investment Seminar 2012 Matthias Zachert Chief Financial Officer New York, January 11, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationCheuvreux German Corporate Conference 2012
Cheuvreux German Corporate Conference 2012 Matthias Zachert Chief Financial Officer Frankfurt, January 17, 2012 Agenda 1 The Merck Group 2 Key strengths 3 Unlocking value 4 Financials 5 Summary 2 Merck
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationLEADING VERTICALLY INTEGRATED GENERIC PLAYER
LEADING VERTICALLY INTEGRATED GENERIC PLAYER March 2018 Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationIndian Pharmaceutical Industry. January 2018
Indian Pharmaceutical Industry January 2018 Introduction The pharmaceutical Industry around the world is one of the fastest growing industries and a major contributor to the world economy. 2020 55 1400
More informationManagement Discussion and Analysis for the First quarter of FY
Management Discussion and Analysis for the First quarter of FY 2015 16 Revenue Figures Consolidated (Rs. In Millions) Q1 FY 2015-16 Q1 FY 2014-15 Growth % India 4,729.30 3,971.59 19.08% US 5,610.46 4,886.70
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationPROFILE OF an EmERgIng GLOBAL LEADER
PROFILE OF an emerging GLOBAL LEADER 1 2 Today is the beginning of an exciting journey at Sun Pharma. With two companies coming together, we are creating a new organization that will be better than the
More informationPHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India)
PHARMACEUTICALS EXPORT PROMOTION COUNCIL (Set up by Ministry of Commerce, Govt. of India) COPY Date : 23-02-2010 News / Story reproduced with thanks:- Stockmarkest.com Indian pharmaceutical industry has
More informationManagement Discussion and Analysis for the Second quarter of FY
Management Discussion and Analysis for the Second quarter of FY 2016 17 Revenue Figures Consolidated (Rs. In Millions) Average conversion rate in Q2 FY 2016 17 considered is 66.85 /USD 1.00 Average conversion
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationMayne Group Limited. ABN AMRO Global Generic Pharmaceutical Conference. Mr Mark Bisset Vice President Global Business Development
Mayne Group Limited ABN AMRO Global Generic Pharmaceutical Conference Mr Mark Bisset Vice President Global Business Development 9 March 2005 Mumbai, India Forward-Looking Statement Comments will be made
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationDr. Reddy s Laboratories Limited Q4 and Full year ended March 31, 2012 Earnings Call Transcript
Dr. Reddy s Laboratories Limited Q4 and Full year ended March 31, 2012 Earnings Call Transcript Kedar Upadhye (Investor Relations) Good morning and good evening to all, and thank you for joining us today
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management s current expectations
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationInvestor Presentation. September 2018
Investor Presentation September 2018 Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties
More informationInvestor presentation. December 2018
Investor presentation December 2018 Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties
More informationSecond Quarter Fiscal Earnings Call Transcript
========================================================================= Second Quarter Fiscal 2007 ========================================================================= Nikhil Shah Thank you, Monali.
More informationTCS Financial Results
TCS Financial Results Quarter I FY 2016-17 July 14, 2016 1 Copyright 2014 Tata Consultancy Services Limited Disclaimer Certain statements in this release concerning our future prospects are forward-looking
More informationCadila Healthcare Limited Investor Presentation November 2012
Cadila Healthcare Limited Investor Presentation November 2012 Well integrated pharma player with global footprints ~60 years Operational experience $ 1 bn + Global Revenues >6% of sales Spent on R&D annually
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More informationBiocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr
Press Release Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr FY18 Revenue Rs 4,336 Cr; EBITDA at Rs 1,035 Cr; Net Profit at Rs 372 Cr Bengaluru, Karnataka,
More informationSustained impetus across verticals drives Biocon s Q1 growth
Bangalore, India July 25, 2012 Sustained impetus across verticals drives Biocon s Q1 growth Revenues at ` 593 Crores; EBITDA at ` 139 Crores; PAT at ` 79 Crores Commenting on the results, Chairman and
More informationManagement Discussion and Analysis for the Third quarter of FY
Management Discussion and Analysis for the Third quarter of FY 2012-13 Revenue Figures Consolidated INR in Millions Third quarter ended Dec 31, Nine months ended Dec 31 FY 2012-13 FY 2011-12 Growth % FY
More informationDr. Reddy s Laboratories Limited Q2 FY13 Earnings Call Transcript
Dr. Reddy s Laboratories Limited Q2 FY13 Earnings Call Transcript Page 1 of 24 Kedar Upadhye (Investor Relations) Good morning and good evening to all of you and thank you for joining us today for Dr.
More informationBiocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr
Press Release Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr FY18 Revenue Rs 4,336 Cr; EBITDA at Rs 1,035 Cr; Net Profit at Rs 372 Cr Bengaluru, Karnataka,
More informationJefferies Global Health Care Conference. June 1, 2015
Jefferies Global Health Care Conference June 1, 2015 Forward-Looking Statements This presentation may contain projections, estimates and other forwardlooking statements that involve a number of risks and
More informationLUPIN LIMITED. J.P. Morgan Healthcare Conference January 8 th, Vinita Gupta, CEO
LUPIN LIMITED J.P. Morgan Healthcare Conference January 8 th, 2019 Vinita Gupta, CEO Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements.
More informationManagement Discussion and Analysis for the Financial Year Q3 FY
Management Discussion and Analysis for the Financial Year Q3 FY 2011-12 Revenue Figures Consolidated INR in Millions Third quarter ended Dec 31 Nine months ended Dec 31 Q3 - FY 2011-12 Q3- FY 2010-11 Growth
More informationAugust 25, Lupin Ltd. Building a Global Generics and Specialty Powerhouse Nilesh Gupta Managing Director
August 25, 2014 Lupin Ltd. Building a Global Generics and Specialty Powerhouse Nilesh Gupta Managing Director Disclaimer Materials and information provided during this presentation may contain forward-looking
More informationCadila Healthcare Limited Investor Presentation August 2014
Cadila Healthcare Limited Investor Presentation August 2014 Well integrated pharma player with global footprints >60 years Operational experience $ 1 bn + Global Revenues ~ 7% of sales Spent on R&D annually
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationPiramal Enterprises Limited. Pharma Strategy 31 st Jan 2017
Piramal Enterprises Limited Pharma Strategy 31 st Jan 2017 Pharma business portfolio with strong presence both within and outside India Piramal Pharma FY16 Rev: Rs.3,558 Crores Global Pharma FY16 Rev:
More informationSecond Quarter and Half Year 2016 Results. Wednesday, July 20, 2016
Second Quarter and Half Year 2016 Results Wednesday, July 20, 2016 Safe Harbor Statement Any statements contained in this document that are not historical facts are forward-looking statements as defined
More informationFor personal use only
ANNUAL GENERAL MEETING MINTER ELLISON LEVEL 23, 525 COLLINS ST, MELBOURNE VIC 3000 AT 11.00 AM ON 26 NOVEMBER, 2014 CEO S ADDRESS Thank you Roger. Good morning Ladies and Gentlemen. It is a pleasure to
More information4. Pharmaceuticals Sector and Opportunity Ahead
4. Pharmaceuticals Sector and Opportunity Ahead In general, there are several reasons which justify focusing on pharmaceutical exports. The most important of these reasons is the size of the industry,
More informationAGM PRESENTATION 8 November 2018
AGM PRESENTATION 8 November 2018 OVERVIEW Highlights STRONG FINANCIAL PERFORMANCE WITH MORE THAN 10% GROWTH IN ADJUSTED GROSS PROFIT*, EBITDA* & EPS* EXCELLENT PERFORMANCE BY COMMERCIAL MEDICINES GOOD
More informationBiocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59%
Press Release Biocon Q3FY19 Earnings Revenue at Rs 1,566 Cr, Up 43%; Net Profit at Rs 217 Cr, Up 136% EBITDA at Rs 406 Cr, Up 59% Bengaluru, Karnataka, India: January 24, 2019: Biocon Ltd (BSE code: 532523,
More informationInvestor Presentation. January 12, 2017
Investor Presentation January 12, 2017 SAFE HARBOR STATEMENT This presentation contains certain forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking
More informationInnovative Science Affordable Medicine
Innovative Science Affordable Medicine H1 FY13 Results Presentation : Oct 31, 2012 www.biocon.com Overall Financial Performance H1 FY13 H1 FY12 % Growth Revenue 1,235 1,001 23% EBITDA 305 281 8% 25% 28%
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Copenhagen October 6, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationJP Morgan Healthcare Conference Stefan Oschmann Head of Pharma. San Francisco, January 9, 2012
JP Morgan Healthcare Conference Stefan Oschmann Head of Pharma San Francisco, January 9, 2012 Disclaimer Remarks All comparative figures relate to the corresponding last year s period. From 2007 the Generics
More informationIndian CRAMS players to cram in growth: CARE Ratings
January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register
More informationA Leading Global Health Care Group
A Leading Global Health Care Group Roadshow Benelux June 29/30, 2015 For detailed financial information please see our annual/quarterly reports and/or conference call materials on www.fresenius.com/ir.
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationCadila Healthcare Ltd. Investor Presentation February 2010
Cadila Healthcare Ltd. Investor Presentation February 2010 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1 bn by 2010; we shall achieve
More informationDr. Reddy s Laboratories Limited First Quarter Fiscal 2010 July 21, 2009
First Quarter Fiscal 2010 July 21, 2009 Kedar Upadhye: Thank you Melissa. Good morning and good evening to all the participants and welcome to Dr. Reddy s Earnings conference call for the 1 st quarter
More informationCharles River to Acquire WIL Research Charles River Laboratories International, Inc.
Charles River to Acquire WIL Research 2016 Charles River Laboratories International, Inc. Safe Harbor Statement This presentation includes forward-looking statements within the meaning of the Private Securities
More informationSecond Quarter and Half Year 2018 Financial Highlights. Walldorf, Germany Thursday, July 19, 2018
Second Quarter and Half Year 2018 Financial Highlights Walldorf, Germany Thursday, July 19, 2018 Safe Harbor Statement Any statements contained in this document that are not historical facts are forward-looking
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationTata Consultancy Services. Investor Relations
Tata Consultancy Services Investor Relations April 2011 1 Investor Relations Forward Looking Statement Certain statements in this release concerning our future prospects are forward-looking statements.
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationInvestor Presentation. May 2013
Investor Presentation May 2013 MAHINDRA. A HISTORY OF RISING. We will challenge conventional thinking and innovatively use all our resources to drive positive change in the lives of our stakeholders and
More informationCadila Healthcare Ltd. Investor Presentation August 2010 BSE : NSE : CADILAHC 1
Cadila Healthcare Ltd. Investor Presentation August 2010 BSE : 532321 NSE : CADILAHC 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over $1
More informationThird quarter and first nine months 2017 Results Release. October 19 th, 2017
Third quarter and first nine months 2017 Results Release October 19 th, 2017 Safe harbor statement Any statements contained in this document that are not historical facts are forward-looking statements
More informationPressekonferenz Frankfurt
PK Frankfurt STADA: New Skills Pressekonferenz Frankfurt Sofitel 08. März 2018 New skills Today we are not a true global player Today we have few high entry barrier products NEW SKILLS External and Internal
More informationCadila Healthcare Limited Investor Presentation May 2015
Cadila Healthcare Limited Investor Presentation May 2015 Well integrated pharma player with global footprints >60 years Operational experience ~ $ 1.4 bn Global Revenues ~ 7% of sales Spent on R&D annually
More informationTCS Financial Results
TCS Financial Results Quarter I FY 2017-18 July 13, 2017 1 Copyright 2017 Tata Consultancy Services Limited Disclaimer Certain statements in this release concerning our future prospects are forward-looking
More informationAmerisourceBergen. J.P. Morgan Healthcare Conference. Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO.
AmerisourceBergen J.P. Morgan Healthcare Conference Steve Collis, Chairman, President & CEO Tim Guttman, EVP & CFO January 10, 2017 Cautionary Note Regarding Forward-Looking Statements Certain of the statements
More informationCB&I Investor Presentation March 2017
A World of Solutions CB&I Investor Presentation March 2017 A Leading Provider of Technology and Infrastructure for the Energy Industry Safe Harbor Statement This presentation contains forward-looking statements
More informationLeading domestic players in India s pharmaceutical market in 2015
THE INDIAN PHARMACEUTICAL MARKET LEADING DOMESTIC COMPANIES 2015 Leading domestic players in India s pharmaceutical market in 2015 1 Executive Summary 1.1 Executive Summary 1.2 Research and Analysis Methods
More informationWest Pharmaceutical Services, Inc. J.P. Morgan Healthcare Conference. Eric M. Green, President & CEO January 9, 2019
West Pharmaceutical Services, Inc. J.P. Morgan Healthcare Conference Eric M. Green, President & CEO January 9, 2019 Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform
More information2018 Wells Fargo Healthcare Conference
2018 Wells Fargo Healthcare Conference September 5, 2018 Shawn Cavanagh Executive VP & COO Forward-Looking Statements & Non-GAAP Financial Measures Statements in this presentation regarding the future
More informationBiocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore Net Profit Up 17% at Rs 147 Crore
Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore Net Profit Up 17% at Rs 147 Crore Bengaluru, India: July 21, 2016 Biocon Ltd (BSE code:
More informationQ4 PAT at Rs 377 crores, up 37% QoQ Annual revenue up 25% and PAT up 18%
Q4 PAT at Rs 377 crores, up 37% QoQ Annual revenue up 25% and PAT up 18% Press Release - Mumbai, India, May 21, 2013 Tech Mahindra, India s leading software exporter today announced audited consolidated
More informationDr. Reddy s Laboratories Limited. Q1 FY13 Earnings Call Transcript
Dr. Reddy s Laboratories Limited Q1 FY13 Earnings Call Transcript Page 1 of 25 Kedar Upadhye (Investor Relations) Good morning and good evening to all, and thank you for joining us today for Dr. Reddy
More informationPress Release. Commenting on the quarterly performance and highlights, Chairperson & Managing Director Kiran Mazumdar-Shaw, stated:
Press Release Biocon Q2FY19 Revenue at Rs 1,375 Cr, Up 35%; EBITDA at Rs 394 Cr, Up 69%; Net Profit at Rs 355 Cr; Net Profit (excluding exceptional income) at Rs 184 Cr; Up 167% Bengaluru, Karnataka, India:
More informationDeutsche Bank s 32nd Annual Health Care Conference May 3, 2007
Deutsche Bank s 32nd Annual Health Care Conference May 3, 2007 Safe Harbor This presentation contains certain forward-looking statements. These statements are based on the current estimates and assumptions
More informationStrategic Overview of the Biotechnology Industry
Strategic Overview of the Biotechnology Industry Cavan Redmond Executive Vice President General Manager Wyeth BioPharma Business Unit June 15, 2004 2003Wyeth. Risk and Innovation Create Opportunity Biotech
More informationLEADING VERTICALLY INTEGRATED GENERIC PLAYER
LEADING VERTICALLY INTEGRATED GENERIC PLAYER February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating
More informationCadila Healthcare Ltd. Investor Presentation November 2010 BSE : NSE : CADILAHC 1
Cadila Healthcare Ltd. Investor Presentation November 2010 BSE : 532321 NSE : CADILAHC 1 Our Vision Zydus shall be a leading global healthcare provider with a robust product pipeline and sales of over
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited Company Presentation Rodman & Renshaw Annual Investment Conference September 9, 2014 Stefan Cross, President Mayne Pharma USA Mayne Pharma is a diverse global pharma company
More informationInvestor Presentation. January 2019
Investor Presentation January 2019 Forward-Looking Statements & Non-GAAP Financial Measures Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects,
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationDr. Reddy s Laboratories Limited FY07 Results Conference Call May 18, 2007
Dr. Reddy s Laboratories Limited FY07 Results Conference Call May 18, 2007 Moderator: Good evening ladies and gentlemen. I am Prathibha, the moderator for this conference. Welcome to Dr. Reddy s Laboratories
More informationManagement Discussion and Analysis for the Financial Year Q1FY Revenue Figures Consolidated Q1 - FY
Management Discussion and Analysis for the Financial Year Q1FY 2013-14 Revenue Figures Consolidated Q1 - FY 2013-14 INR in Millions Q1- FY 2012-13 Growth % Speciality Business India 3,285.83 2,797.88 17.44%
More informationASX Announcement MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS
22 February 2019 MAYNE PHARMA REPORTS STRONGER 1HFY19 RESULTS Revenues of $274.4m, an increase of 13% on 1HFY18 Reported EBITDA of $65.4m, an increase of 184% on 1HFY18 Underlying EBITDA of $81.2m, an
More information